This protocol addresses the management of classical Hodgkin lymphoma in patients aged 18 years or younger whose disease has either returned after prior treatment (relapsed) or did not respond to initial treatment (refractory).
Children and adolescents — age 18 years or younger — with classical Hodgkin lymphoma that has relapsed (come back after treatment) or is refractory (did not respond to initial treatment). This population requires a distinct treatment approach tailored to their age group and disease course.
The approach for this population centres on high-dose chemotherapy combined with autologous stem cell transplantation — a procedure that uses the patient's own stem cells. Additional treatment considerations apply depending on patient risk profile.
Full regimen details, eligibility criteria, sequencing, and post-transplant management are available in the complete protocol below.
Treatments for Children and Adolescents with Relapsed or Refractory Classical Hodgkin Lymphoma.
Treatment options for children and adolescents whose disease has relapsed (come back after treatment) or is refractory (did not respond to initial treatment).
High-dose chemotherapy with autologous stem cell transplantation, which uses the patient's own stem cells; brentuximab vedotin may also be given.
View source ↗